A Multicenter, Uncontrolled, Nonrandomized, Open-Label, Phase 1/2 Trial Investigating the Safety and Efficacy of OPC 415 in MMG49 Antigen-Positive Patients With Relapsed and/or Refractory Multiple Myeloma
Latest Information Update: 25 Apr 2022
At a glance
- Drugs Anti-MMG49 chimeric antigen receptor T cell therapy Osaka University/Otsuka Pharmaceutical (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 24 Dec 2020 Status changed from not yet recruiting to recruiting.
- 08 Dec 2020 New trial record